BACKGROUND Adults with diabetes and other conditions are at increased risk of severe
RSV disease and hospitalization. In a phase 3 placebo-controlled study (NCT04886596) in …

Background: Adults with diabetes and other conditions are at increased risk of severe RSV
disease and hospitalization. In a phase 3 placebo-controlled study (NCT04886596) in …

Background Older adults with chronic cardiorespiratory or endocrine/metabolic conditions
are at increased risk of respiratory syncytial virus (RSV)-related acute respiratory illness …

Introduction/Aim: RSV can cause severe respiratory disease in older adults with
cardiorespiratory conditions. In an ongoing phase 3 placebo-controlled study …

Background Respiratory syncytial virus (RSV) is an important cause of acute respiratory
infection, lower respiratory tract disease, clinical complications, and death in older adults …

Background RSVPreF3 OA was recently approved by the United States FDA for the
prevention of RSV-related lower respiratory tract disease (RSV-LRTD) in adults≥ 60 years …

Background Respiratory syncytial virus (RSV) is a contagious pathogen causing acute
respiratory infections (ARIs). Symptoms range from mild upper respiratory tract infections to …

Background Respiratory syncytial virus (RSV) infection causes considerable illness in older
adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein–based …

Background The adjuvanted RSV prefusion F protein–based vaccine (RSVPreF3 OA) was
efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in≥ 60-years …

Patient Population: Inclusion criteria Participants≥ 60 years of age at the time of first
vaccination, who were medically stable, living in the community or in a long-term care …